TY - JOUR T1 - Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area JF - medRxiv DO - 10.1101/2020.09.22.20199125 SP - 2020.09.22.20199125 AU - S. Wesley Long AU - Randall J. Olsen AU - Paul A. Christensen AU - David W. Bernard AU - James J. Davis AU - Maulik Shukla AU - Marcus Nguyen AU - Matthew Ojeda Saavedra AU - Prasanti Yerramilli AU - Layne Pruitt AU - Sishir Subedi AU - Hung-Che Kuo AU - Heather Hendrickson AU - Ghazaleh Eskandari AU - Hoang A. T. Nguyen AU - J. Hunter Long AU - Muthiah Kumaraswami AU - Jule Goike AU - Daniel Boutz AU - Jimmy Gollihar AU - Jason S. McLellan AU - Chia-Wei Chou AU - Kamyab Javanmardi AU - Ilya J. Finkelstein AU - James M. Musser Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/25/2020.09.22.20199125.abstract N2 - We sequenced the genomes of 5,085 SARS-CoV-2 strains causing two COVID-19 disease waves in metropolitan Houston, Texas, an ethnically diverse region with seven million residents. The genomes were from viruses recovered in the earliest recognized phase of the pandemic in Houston, and an ongoing massive second wave of infections. The virus was originally introduced into Houston many times independently. Virtually all strains in the second wave have a Gly614 amino acid replacement in the spike protein, a polymorphism that has been linked to increased transmission and infectivity. Patients infected with the Gly614 variant strains had significantly higher virus loads in the nasopharynx on initial diagnosis. We found little evidence of a significant relationship between virus genotypes and altered virulence, stressing the linkage between disease severity, underlying medical conditions, and host genetics. Some regions of the spike protein - the primary target of global vaccine efforts - are replete with amino acid replacements, perhaps indicating the action of selection. We exploited the genomic data to generate defined single amino acid replacements in the receptor binding domain of spike protein that, importantly, produced decreased recognition by the neutralizing monoclonal antibody CR30022. Our study is the first analysis of the molecular architecture of SARS-CoV-2 in two infection waves in a major metropolitan region. The findings will help us to understand the origin, composition, and trajectory of future infection waves, and the potential effect of the host immune response and therapeutic maneuvers on SARS-CoV-2 evolution.IMPORTANCE There is concern about second and subsequent waves of COVID-19 caused by the SARS-CoV-2 coronavirus occurring in communities globally that had an initial disease wave. Metropolitan Houston, Texas, with a population of 7 million, is experiencing a massive second disease wave that began in late May 2020. To understand SARS-CoV-2 molecular population genomic architecture, evolution, and relationship between virus genotypes and patient features, we sequenced the genomes of 5,085 SARS-CoV-2 strains from these two waves. Our study provides the first molecular characterization of SARS-CoV-2 strains causing two distinct COVID-19 disease waves.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are indebted to Drs. Marc Boom and Dirk Sostman for their support, and to many very generous Houston philanthropists for their tremendous support of this ongoing project, including but not limited to anonymous, Ann and John Bookout III, Carolyn and John Bookout, Ting Tsung and Wei Fong Chao Foundation, Ann and Leslie Doggett, Freeport LNG, the Hearst Foundations, Jerold B. Katz Foundation, C. James and Carole Walter Looke, Diane and David Modesett, the Sherman Foundation, and Paula and Joseph C. (Rusty) Walter III.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Houston Methodist IRB Approved Protocol IRB1010-0199All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SARS-CoV-2 genomes described herein have all been deposited in GISAID and are publically available. ER -